JPMorgan Chase & Co. Cuts Humana (NYSE:HUM) Price Target to $180.00

Humana (NYSE:HUM) had its price target reduced by JPMorgan Chase & Co. from $274.00 to $180.00 in a research report sent to investors on Friday morning,MarketScreener reports. They currently have a neutral rating on the insurance provider’s stock.

HUM has been the subject of a number of other research reports. Barclays reaffirmed an “underperformer” rating on shares of Humana in a research report on Monday, January 5th. KeyCorp restated a “sector weight” rating on shares of Humana in a research report on Friday, December 12th. UBS Group dropped their price objective on Humana from $285.00 to $195.00 and set a “neutral” rating for the company in a research note on Thursday. Robert W. Baird cut their price objective on Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. Finally, Jefferies Financial Group lowered their target price on Humana from $310.00 to $235.00 and set a “buy” rating for the company in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat, Humana has a consensus rating of “Hold” and an average target price of $238.29.

Humana Stock Up 2.8%

Shares of NYSE:HUM opened at $183.92 on Friday. The business has a 50-day moving average price of $244.65 and a 200 day moving average price of $261.02. The company has a current ratio of 2.00, a quick ratio of 2.02 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $22.12 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 1.96 and a beta of 0.44. Humana has a 12-month low of $169.61 and a 12-month high of $315.35.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. Humana had a net margin of 0.92% and a return on equity of 11.43%. The company had revenue of $32.64 billion for the quarter, compared to analysts’ expectations of $32.08 billion. During the same quarter in the prior year, the company posted ($2.16) earnings per share. Humana’s revenue for the quarter was up 11.3% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Sell-side analysts expect that Humana will post 16.47 EPS for the current year.

Hedge Funds Weigh In On Humana

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Humana by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock valued at $3,652,890,000 after acquiring an additional 106,030 shares in the last quarter. Dodge & Cox increased its position in shares of Humana by 5.6% in the 2nd quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock valued at $2,775,562,000 after purchasing an additional 597,705 shares during the last quarter. Capital International Investors increased its position in shares of Humana by 113.9% in the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after purchasing an additional 3,097,571 shares during the last quarter. State Street Corp raised its holdings in shares of Humana by 1.8% in the 4th quarter. State Street Corp now owns 5,462,549 shares of the insurance provider’s stock valued at $1,403,877,000 after purchasing an additional 97,211 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Humana by 28.9% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock worth $1,151,759,000 after purchasing an additional 1,008,514 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana News Summary

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.